Movement Disorders

A recent study showed improvements in animals with mutant huntingtin protein treated with AFFiRiS AG’s investigational monoclonal antibody.

Here's what is coming soon to NeurologyLive.

A recent study identified 3 novel loci that are associated with Parkinson disease progression to dementia: RIMS2, TMEM108, and WWOX.

Neurology News Network for the week ending May 8, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 7, 2021.

The director of the Center for Neurological Restoration at Cleveland Clinic spoke to how identifying care gaps in Parkinson disease patients is not a niche issue, but part of a bigger problem.

The neurologist at University of Utah discussed the potential of using teleneurology to diagnose neurological conditions.

Leaders in neurology discuss the development of infusion formulations of apomorphine and levodopa/carbidopa as well as oral agents with novel mechanisms of extended-release delivery.

Laxman Bahroo, DO and Mindy K. Bixby, DO provide insight into factors to consider for patients with challenging off time including surgical and device-assisted therapeutic options.

In preclinical data, VY-HTT01 showed a robust and durable reduction of huntingtin mRNA and protein while distributed across core areas of Huntington disease pathology.

A survey of more than 500 individuals also found that dyskinesia impacted social interactions and reported that OFF time was isolating.

Here's what is coming soon to NeurologyLive.

AbbVie recently announced a new phase 3 study (NCT04380142), called M15-736, which will measure the efficacy, safety, and tolerability of continuous subcutaneous infusion of ABBV-951.

The chief scientific officer of the Parkinson’s Foundation and adjunct associate professor in the Department of Neuroscience and Physiology at New York University School of Medicine discussed the adoption of telemedicine in Parkinson disease care.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 30, 2021.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD.

A trio of clinicians from Georgetown University explore the current status of disease-modifying therapies for individuals with Parkinson disease.

The director of the Center for Neurological Restoration at Cleveland Clinic provided an inside perspective on how the MANAGE-PD tool can effectively assist in the Parkinson disease screening process.

Surgical care for PD is safe and effective, and should no longer be treated as a consideration of last resort, but as a treatment option discussed early in the disease course with the patient and their family.

Expert neurologists consider the advantages and disadvantages of oral agents for OFF time in Parkinson’s Disease such as opicapone, extended-release amantadine, and istradefylline.

Experts in Parkinson’s Disease build a discussion on the use of levodopa inhalation powder for the management of OFF time and reflect on patients’ considerations when switching therapies.

Guest Editor-in-Chief Jill Giordano Farmer, DO, MPH, shared her perspective on the importance of April as the annual Parkinson disease awareness month.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 23, 2021.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Daniel Claassen, MD, MS.